Sandhill Capital Partners’s Novo Nordisk NVO Stock Holding History

Sandhill Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,582	Closed	-$222K	–	101
2024 Q4	$222K	Sell	2,582 -100	-4%	-$10.8K	0.02%	86
2024 Q3	$319K	Buy	2,682 +100	+4%	+$13.3K	0.02%	80
2024 Q2	$369K	Hold	2,582	–	–	0.03%	75
2024 Q1	$332K	Sell	2,582 -500	-16%	-$59.5K	0.03%	75
2023 Q4	$319K	Hold	3,082	–	–	0.03%	72
2023 Q3	$280K	Hold	3,082	–	–	0.03%	77
2023 Q2	$249K	Hold	3,082	–	–	0.02%	75
2023 Q1	$245K	Sell	3,082 -600	-16%	-$42.5K	0.02%	73
2022 Q4	$249K	Buy	+3,682	New	+$216K	0.03%	75
2022 Q3	–	Sell	-3,682	Closed	-$205K	–	88
2022 Q2	$205K	Hold	3,682	–	–	0.02%	79
2022 Q1	$204K	Buy	+3,682	New	+$189K	0.02%	83

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Sandhill Capital Partners's NVO Position: Q1 2025 in Review

Sandhill Capital Partners sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,582 shares — an estimated $222K sold.

Sandhill Capital Partners first reported a position in NVO in Q1 2022 and held it in 11 quarters. The position peaked at $369K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

Sandhill Capital Partners reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
Sandhill Capital Partners sold 2,582 Novo Nordisk shares in Q1 2025, an estimated $222K.
Sandhill Capital Partners first reported a position in Novo Nordisk in Q1 2022 and held it in 11 quarters.
Sandhill Capital Partners's Novo Nordisk position peaked at $369K in Q2 2024.
1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Sandhill Capital Partners's 13F filing for Q1 2025, filed 14 May 2025.